Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration

Objective To report the visual and anatomic outcome of intravitreal bevacizumab (Avastin) injections in the treatment of subfoveal neovascular age-related macular degeneration (AMD). Methods Interventional, consecutive, retrospective case series. Sixty-five eyes of 65 patients with subfoveal neovasc...

Full description

Saved in:
Bibliographic Details
Published in:International ophthalmology 2009-10, Vol.29 (5), p.349-357
Main Authors: Levy, Jaime, Shneck, Marina, Rosen, Shirley, Klemperer, Itamar, Rand, David, Weinstein, Orly, Pitchkhadze, Anry, Belfair, Nadav, Lifshitz, Tova
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Angiogenesis Inhibitors - administration & dosage
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Humanized
Bevacizumab
Female
Follow-Up Studies
Fovea Centralis - blood supply
Humans
Injections, Intraocular
Macular Degeneration - complications
Macular Degeneration - pathology
Macular Degeneration - physiopathology
Male
Medicine
Medicine & Public Health
Neovascularization, Pathologic - drug therapy
Neovascularization, Pathologic - etiology
Neovascularization, Pathologic - pathology
Neovascularization, Pathologic - physiopathology
Ophthalmology
Original Paper
Retina - drug effects
Retina - pathology
Retrospective Studies
Treatment Outcome
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Visual Acuity - drug effects
Vitreous Body
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To report the visual and anatomic outcome of intravitreal bevacizumab (Avastin) injections in the treatment of subfoveal neovascular age-related macular degeneration (AMD). Methods Interventional, consecutive, retrospective case series. Sixty-five eyes of 65 patients with subfoveal neovascular age-related macular degeneration (AMD) received three intravitreal bevacizumab (1.25 mg) injections. Outcome measures included visual acuity (VA), central retinal thickness (CRT), and size of lesion at 24 or more weeks follow-up. Results Thirty-five eyes had prior treatment with photodynamic therapy (PDT). At presentation, VA was 1.12 ± 0.62 logMAR, CRT was 305 ± 115 μm, and greatest linear diameter (GLD) of the lesion was 4,902 ± 1,861 μm. There was no statistically significant difference between previous PDT and naïve eyes in VA, CRT, and GLD at presentation. After three bevacizumab injections, VA, CRT, and GLD significantly improved ( P  
ISSN:0165-5701
1573-2630
DOI:10.1007/s10792-008-9243-1